The first major finding of the present research is that a significant proportion (50.9%) of remitted RRMS patients show activated IRS and CIRS, M1, Th1, Th17, and T-cell growth factor profiles. This evidence concerns the gene TBXT and relapsing-remitting multiple sclerosis.